Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation

American Journal of Transplantation

Volumn 7, Issue 6, 2007, Pages 1648-1655

  Comoli, P ^a   Basso, S ^a   Zecca, M ^a   Pagliara, D ^a   Baldanti, F ^b   Bernardo, M E ^a   Barberi, W ^a   Moretta, A ^a   Labirio, M ^a   Paulli, M ^a   Furione, M ^b   Maccario, R ^a   Locatelli, F ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Cytotoxic T lymphocytes; Epstein Barr virus; Pediatric hematopoietic stem cell transplantation; Posttransplant lymphoproliferative disorder; Rituximab

Indexed keywords

CD19 ANTIGEN; CD20 ANTIBODY; CD20 ANTIGEN; CYCLOSPORIN A; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; BLOOD; CELL THERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HAPLOIDY; HEMATOLOGIC MALIGNANCY; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; T CELL DEPLETION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS INFECTION; VIRUS INHIBITION; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; INFANT; LYMPHOCYTE DEPLETION; LYMPHOPROLIFERATIVE DISORDERS; MALE; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING;

EID: 34248659404     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.01823.x     Document Type: Article

References (31)

1. Aversa F, Tabilio A, Velardi A et al. Treatment of high risk acute leukemia with T-cell depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998 339 : 1186 1193.
2. Klingebiel T, Handgretinger R, Lang P et al. Haploidentical transplant for acute lymphoblastic leukemia in childhood. Blood Rev 2004 18 : 181 192.
3. Eyrich M, Lang P, Shangara L et al. A prospective analysis of the pattern of immune reconstitution in a pediatric cohort following transplantation of positively-selected human leucocyte antigen-disparate hematopoietic stem cells from parental donors. Br J Hematol 2001 114 : 422 432.
4. Broers AEC, Van Der Holt R, van Esser JWJ et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell depleted stem cell transplantation. Blood 2000 95 : 2240 2245.
5. Shapiro RS, McClain K, Frizzera G et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988 71 : 1234 1243.
6. Zutter MM, Martin PJ, Sale GE et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988 72 : 520 529.
7. Gerritsen EJ, Stam ED, Hermans J et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders BLPD after non-HLA identical BMT in children. Bone Marrow Transplant 1996 18 : 377 382.
8. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997 15 : 405 431.
9. Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 1999 94 : 2208 2216.
10. Gross TG, Steinbuch M, DeFor T et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: Risk factors, treatment and outcome. Bone Marrow Transplant 1999 23 : 251 258.
11. Rooney CM, Smith CA, Ng C et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995 345 : 9 13.
12. Kuehnle I, Huls MH, Liu Z et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000 95 : 1502 1505.
13. Milpied N, Vasseur B, Parquet N et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 2000 11 : 113 116.
14. van Esser JWJ, Niesters HGM, Van Der Holt B et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high risk patients after allogeneic stem cell transplantation. Blood 2002 99 : 4364 4369.
15. Baldanti F, Grossi P, Furione M et al. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol 2000 38 : 613 619.
16. Achille A, Scarpa A, Montresor M et al. Routine application for polymerase chain reaction in the diagnosis of monoclonality of B-cell lymphoid proliferations. Diagn Mol Pathol 1995 4 : 14 24.
17. Comoli P, Labirio M, Basso S et al. Infusion of autologous Epstein-Barr virus(EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002 99 : 2592 2598.
18. Comoli P, Pedrazzoli P, Maccario R et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous EBV-targeted cytotoxic T-lymphocytes. J Clin Oncol 2005 23 : 8942 8949.
19. Comoli P, Rooney CM. Treatment of Epstein-Barr virus infections: Chemotherapy, antiviral therapy, and immunotherapy. In : Tselis A. Jenson HB, eds. Epstein-Barr Virus. New York : Taylor and Francis Group, 2006 : 353 374.
20. Fischer A, Blanche S, LeBidois J et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991 324 : 1451 1456.
21. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes as treatment of Epstein-Barr virus associated lymphoproliferative disorders complicating allogeneic marrow transplantation. N Engl J Med 1994 330 : 1185 1191.
22. Straathof KC, Savoldo B, Heslop HE, Rooney CM. Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol 2002 118 : 728 740.
23. Comoli P, Maccario R, Locatelli F et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 2005 5 : 1415 1422.
24. Gottschalk S, Ng CYC, Smith CA et al. An Epstein-Barr virus deletion mutant that causes fatal lymphoproliferative disease unresponsive to virus-specific T cell therapy. Blood 2001 97 : 835 843.
25. Perruccio K, Tosti A, Burchielli E et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005 106 : 4397 4406.
26. Choquet S, Leblond V, Herbrecht R et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006 107 : 3053 3057.
27. Porcu P, Eisenbeis CF, Pelletier RP et al. Successful treatment of posttransplant lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8 +T-cell restoration. Blood 2002 100 : 2341 2348.
28. Meij P, van Esser JWJ, Niesters HGM et al. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-cell depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003 101 : 4290 4297.
29. Savoldo B, Rooney CM, Quiros-Tejeira RE et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005 5 : 566 572.
30. Locatelli F, Maccario R, Comoli P et al. Hematopoietic and immune recovery after transplantation of cord blood progenitor cells in children. Bone Marrow Transplant 1996 18 : 1095 1101.
31. Heslop HE, Ng CYC, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996 2 : 551 555.